Cross-Sector entity
Therapeutic Goods Administration (TGA) is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Cross-Sector stories that mention Bilal Cassim, all published on March 20, 2026.
2 verified stories tracked
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Therapeutic Goods Administration (TGA) is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Cross-Sector stories that mention Bilal Cassim, all published on March 20, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bilal Cassim. Shared-story counts are live from our verified record — not editorial picks.
Bilal Cassim’s public testimony regarding the efficacy of medicinal cannabis for PTSD and sleep disorders highlights a growing trend of patient-led advocacy in Australia. This case underscores the shifting clinical landscape as researchers and regulators grapple with the integration of cannabinoid therapies into standard psychiatric care.
The public endorsement of medicinal cannabis by patients like Bilal Cassim for PTSD and insomnia highlights a significant shift in Australian healthcare toward cannabinoid therapies. This trend reflects a broader move toward alternative mental health treatments as the clinical and regulatory landscape continues to evolve.
